跳往主要內容

Developing Bismuth Drugs to Fight COVID-19

Bismuth drugs to fight emerging infectious diseases

(From left) Dr Jasper Chan and Dr Shuofeng Yuan, Professor Hongzhe Sun and Dr Runming Wang with the molecular structure of RBC at the press conference on their findings of bismuth drug

(From left) Dr Jasper Chan and Dr Shuofeng Yuan, Professor Hongzhe Sun and Dr Runming Wang with the molecular structure of RBC at the press conference on their findings of bismuth drug

(From left) Professor Hongzhe Sun’s research team: Dr Hongyan Li, Professor Hongzhe Sun, Dr Runming Wang and Dr Shuofeng Yuan

(From left) Professor Hongzhe Sun’s research team: Dr Hongyan Li, Professor Hongzhe Sun, Dr Runming Wang and Dr Shuofeng Yuan

Representative images of the viral N protein distribution in lung tissue sections from infected hamsters treated with DMSO (top), Remdesivir (middle) and RBC (bottom), respectively

Representative images of the viral N protein distribution in lung tissue sections from infected hamsters treated with DMSO (top), Remdesivir (middle) and RBC (bottom), respectively

Proposed structure of Bi-bound zinc-bindnig domain of SARS-CoV-2 helicase. Through kicking out the crucial zinc(II) ions in the zinc-binding domain of SARS-CoV-2 helicase, RBC demonstrated its ability to potently suppress the replication of SARS-CoV-2

Proposed structure of Bi-bound zinc-bindnig domain of SARS-CoV-2 helicase. Through kicking out the crucial zinc(II) ions in the zinc-binding domain of SARS-CoV-2 helicase, RBC demonstrated its ability to potently suppress the replication of SARS-CoV-2

請參閱英文版

返回專題故事